此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

研究 Carisbamate 作为辅助治疗儿童和成人 LGS 相关癫痫发作的疗效和安全性

2026年11月3日 更新者:SK Life Science, Inc.

一项随机、双盲、安慰剂对照研究,旨在调查 Carisbamate (YKP509) 作为儿童和成人 Lennox-Gastaut 综合征相关癫痫发作的辅助治疗的疗效和安全性,可选择开放标签扩展

The primary objective is to evaluate the efficacy of carisbamate (YKP509) as adjunctive treatment in reducing the number of drop seizures (tonic, atonic, and tonic-clonic) compared with placebo in pediatric and adult subjects (age 4-55 years) diagnosed with Lennox Gastaut Syndrome (LGS).

研究概览

地位

招聘中

详细说明

The secondary objectives are:

  • To evaluate the efficacy of carisbamate (YKP509) as adjunctive treatment in reducing the total number of seizures compared with placebo in pediatric and adult subjects diagnosed with Lennox Gastaut Syndrome (LGS)
  • Evaluate the safety, tolerability of carisbamate in the LGS population
  • Evaluate steady-state pharmacokinetics of carisbamate in subjects with Lennox Gastaut.

研究类型

介入性

注册 (估计的)

252

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

      • Beersheba、以色列
        • 完全的
        • Soroka University Medical Centre
      • Jerusalem、以色列、91220
        • 完全的
        • Hadassah Medical Center
      • Ramat Gan、以色列
        • 完全的
        • Sheba Medical Center
    • Tel Aviv
      • Tel Aviv、Tel Aviv、以色列
        • 完全的
        • Tela Viv Sourlasky Medical Center
      • Budapest、匈牙利
        • 完全的
        • Orszagos Mentalis, Ideggyogyaszati es Idegsebezeti Intezet
      • Budapest、匈牙利
        • 招聘中
        • Semmelweis Egyetem Idegsebeszeti es Neurointervencios Klinika
        • 接触:
          • Anna Sakovics, MD
      • Taipei、台湾
        • 招聘中
        • Taipei Veterans General Hospital
        • 首席研究员:
          • Ting-Rong Hsu, MD
      • Taipei、台湾
        • 招聘中
        • National Taiwan University Hospital
        • 首席研究员:
          • Wang-Tso Lee, MD
      • Taoyuan、台湾
        • 完全的
        • Chang Gung Memorial Hospital
      • Barranquilla、哥伦比亚
        • 撤销
        • Fundacion Hospital Universidad del Norte
      • Cali、哥伦比亚
        • 撤销
        • Fundacion Valle del Lili/Clinic - Outpatient
      • Envigado、哥伦比亚
        • 完全的
        • CliniSalud del Sur S.A.S - Centro de Investigación
      • Medellín、哥伦比亚
        • 完全的
        • Hospital Pabloe Tubon Uribe
      • Medellín、哥伦比亚
        • 完全的
        • Institutio Neurologico de Colombia
      • Belgrade、塞尔维亚
        • 招聘中
        • University Clinical Center of Serbia - PPDS
        • 首席研究员:
          • Dragoslav Sokic, MD
      • Kragujevac、塞尔维亚
        • 招聘中
        • University Clinical Center Kragujevac
        • 首席研究员:
          • Aleksandar Gavrilovic, MD
      • Niš、塞尔维亚
        • 招聘中
        • University Clinical Center Nis
        • 首席研究员:
          • Tatjana Tosic, MD
      • Novi Sad、塞尔维亚
        • 招聘中
        • Children and Youth Health Care Institute of Vojvodina
        • 首席研究员:
          • Marija Knezevic-Pogancev, MD
        • 接触:
          • Tatjana Redzek Mudrinic, MD
    • Belgrade
      • Belgrade、Belgrade、塞尔维亚
        • 招聘中
        • Childrens University Hospital
        • 首席研究员:
          • Dimitrije Nikolic, MD
      • Culiacán、墨西哥
        • 招聘中
        • Neurociencias Estudios Clinicos S.C.
        • 首席研究员:
          • Elmer Lopez Meza, MD
      • Mexico City、墨西哥、06700
        • 招聘中
        • Clinstile, S.A. de C.V.
        • 首席研究员:
          • Sandra Quinones, MD
    • Jalisco
      • Guadalajara、Jalisco、墨西哥
        • 招聘中
        • Hospital Civil Fray Antonio Alcalde
        • 首席研究员:
          • Hugo Ceja Moreno, MD
    • Attica
      • Marousi、Attica、希腊
        • 完全的
        • Iaso Children's Hospital
    • Bavaria
      • Erlangen、Bavaria、德国
        • 招聘中
        • Universitatsklinikum Erangen
        • 首席研究员:
          • Hajo Martinus Hamer, MD
    • Saxony
      • Radeberg、Saxony、德国
        • 招聘中
        • Kleinwachau Sächsisches Epilepsiezentrum
        • 首席研究员:
          • Nils Holert, MD
      • Florence、意大利
        • 完全的
        • Azienda Ospedaliero Universitaria A Meyer - INCIPIT - PIN
      • Milan、意大利
        • 完全的
        • ASST Santi Paolo E Carlo - Azienda Universitaria-Polo Universitaria - San Paolo
    • Liguria
      • Genoa、Liguria、意大利
        • 招聘中
        • Istituto G Gaslini Ospedale Pediatrico IRCCS - INCIPIT - PIN
        • 首席研究员:
          • Pasquale Striano, MD
    • Lombardy
      • Milan、Lombardy、意大利
        • 招聘中
        • ASST Fatebenefratelli Sacco - Ospedale dei Bambini Vittore Buzzi
        • 首席研究员:
          • Monica Lodi, MD
      • Milan、Lombardy、意大利
        • 招聘中
        • Fondazione IRCCS Di Rilievo Nazionale Instituto
        • 首席研究员:
          • Elena Freri, MD
    • Verona
      • Verona、Verona、意大利
        • 招聘中
        • Azienda Ospedaliera Universitaria Integrata Di Verona
        • 首席研究员:
          • Francesca Darra, MD
      • Krakow、波兰
        • 招聘中
        • Centrum Medyczne Plejady
        • 首席研究员:
          • Marta Zolnowska, MD
    • Greater Poland Voivodeship
      • Poznan、Greater Poland Voivodeship、波兰
        • 完全的
        • Szpital Kliniczny im.H.Swiecickiego Uniwersytetu Medycznego im.K.Marcinkowskiego w Poznaniu-Dluga1/2
      • Heidelberg、澳大利亚
        • 招聘中
        • Austin Hosptial
        • 首席研究员:
          • Ingrid Scheffer, MD
      • Melbourne、澳大利亚
        • 招聘中
        • Alfred Health
        • 首席研究员:
          • Patrick Kwan
      • Nedlands、澳大利亚
        • 完全的
        • Perth's Children Hospital
      • South Brisbane、澳大利亚
        • 完全的
        • Queensland Children's Hospital
    • California
      • Palo Alto、California、美国、94305
        • 招聘中
        • Stanford University Hospital
        • 首席研究员:
          • Brenda Porter, MD
    • Florida
      • Jacksonville、Florida、美国、32209
        • 完全的
        • University of Florida Health Science Center
      • Orlando、Florida、美国、32803
        • 完全的
        • AdventHealth
      • Tampa、Florida、美国、33609
        • 招聘中
        • Pediatric Epilepsy and Neurology Specialists
        • 首席研究员:
          • Jose Ferreira, MD
      • Tampa、Florida、美国、33620
        • 完全的
        • University of South Florida
      • Wellington、Florida、美国、33414
        • 完全的
        • Axcess Medical Research
    • Idaho
      • Boise、Idaho、美国、83702
        • 完全的
        • Consultants in Epilepsy and Neurology PLLC
    • Kentucky
      • Lexington、Kentucky、美国、40504
        • 完全的
        • Bluegrass Epilepsy Research, LLC
    • Louisiana
      • New Orleans、Louisiana、美国、70112
        • 完全的
        • University Medical Center New Orleans
    • Maryland
      • Baltimore、Maryland、美国、21287
        • 招聘中
        • Johns Hopkins Hospital
        • 首席研究员:
          • Joon Yi Kang, MD
      • Bethesda、Maryland、美国、20817
        • 招聘中
        • Mid-Atlantic Epilepsy and Sleep Center
        • 接触:
          • Arkady Barber
        • 首席研究员:
          • Pavel Klein, MD
    • Minnesota
      • Rochester、Minnesota、美国、55905
        • 完全的
        • Mayo Clinic
    • Missouri
      • Columbia、Missouri、美国、65211
        • 完全的
        • University of Missouri School of Medicine
    • New Jersey
      • Hackensack、New Jersey、美国、07601
        • 招聘中
        • Northeast Regional Epilepsy Group
        • 首席研究员:
          • Eric Segal, MD
      • New Brunswick、New Jersey、美国、08901
        • 完全的
        • St. Peters Hospital
    • New York
      • The Bronx、New York、美国、10467
        • 完全的
        • Montefiore
    • North Carolina
      • Durham、North Carolina、美国、27713
        • 招聘中
        • Duke University Clinical Research at Pickett Road
        • 首席研究员:
          • Muhammad Zafar, MD
      • Winston-Salem、North Carolina、美国、27101
        • 完全的
        • Wake Forest University - School of Medicine
    • Pennsylvania
      • Philadelphia、Pennsylvania、美国、19104
        • 招聘中
        • Children's Hospital of Philadelphia
        • 首席研究员:
          • Eric Marsh, MD
    • Texas
      • Austin、Texas、美国、78758
        • 完全的
        • Austin Epilepsy Care Center - Clinic/Outpatient Facility
      • Dallas、Texas、美国、75231
        • 完全的
        • Neurology Consultants of Dallas, PA - Hospital
    • Virginia
      • Winchester、Virginia、美国、22601
        • 完全的
        • Virginia Epilepsy and Neurodevelopmental Clinic at WNC
    • Lisbon District
      • Lisbon、Lisbon District、葡萄牙
        • 招聘中
        • Centro Hospitalar de Lisboa Norte, EPE
        • 首席研究员:
          • Sofia Quintas, MD
      • Lisbon、Lisbon District、葡萄牙
        • 完全的
        • Centro Hospitalar de Lisboa Ocidental, EPE - Hospital Sao Francisco Xavier
    • Porto District
      • Porto、Porto District、葡萄牙
        • 招聘中
        • Centro Hospitalar de Sao Joao, EPE
        • 首席研究员:
          • Raquel Sousa, MD
    • Setúbal District
      • Almada、Setúbal District、葡萄牙
        • 完全的
        • Hospital Garcia de Orta
      • Madrid、西班牙
        • 招聘中
        • Hospital Ruber Internacional (Grupo Quironsalud)
        • 首席研究员:
          • Antonio Gil-Nigel, MD
      • Madrid、西班牙
        • 完全的
        • Hospital Infantil Universitario Niño Jesus - PIN
    • Barcelona
      • Esplugues de Llobregat、Barcelona、西班牙
        • 完全的
        • Hospital Sant Joan de Deu - PIN
    • Córdoba Province
      • Córdoba、Córdoba Province、阿根廷
        • 完全的
        • Hospital de Ninos de La Santisma Trinidad
    • Mendoza Province
      • Mendoza、Mendoza Province、阿根廷
        • 完全的
        • Resolution Psychopharmacology Research Institute
      • Daegu、韩国
        • 完全的
        • Kyungpook National University Chilgok Hospital
      • Seoul、韩国
        • 招聘中
        • Samsung Medical Center
        • 首席研究员:
          • Jee Hun S. Lee, MD
      • Seoul、韩国
        • 招聘中
        • Seoul National University Hospital
        • 首席研究员:
          • Byung Chan Lim, MD

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

4年 至 55年 (孩子、成人)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Subject must have a documented history of Lennox-Gastaut syndrome by:

    1. Evidence of more than one type of seizure, of which at least one should be an atonic or tonic seizure
    2. History of an electroencephalogram (EEG) reporting diagnostic criteria for LGS (abnormal background activity accompanied by slow, spike and wave pattern <3.0 Hz)
    3. History of developmental delay
  2. Male or female subjects

  3. Subjects must be age 4-55 years at the time of consent/assent

  4. Must have been <11 years old at the onset of LGS

  5. Subjects must have experienced at least 2 drop seizures with potential to fall (tonic, atonic, tonic-clonic) during the 4-week Baseline period preceding randomization (minimum of 4 drop seizures in the first two weeks and 4 in the last two weeks). Drop seizures are defined as a seizure involving the entire body, trunk, or head that led or could have led to a fall, injury, slumping in a chair, or hitting the subject's head on a surface. All drop seizure types must be countable (either as isolated seizures or as countable isolated seizures in a cluster).

  6. Subjects must have been receiving 1 to 4 concomitant anti-seizure medications (ASMs) at a stable dose for at least 4 weeks before Visit 1

  7. If not taking Epidiolex, subjects may take other approved cannabidiol or over the counter cannabidiol products. If taking cannabidiol other than Epidiolex, consult Medical Monitor to determine if it counts as a concomitant ASM.

  8. Dietary therapy and any CNS stimulator settings must be stable for 4 weeks prior to baseline and maintain stable regimen throughout the study. The dietary therapy and CNS stimulators are not counted as an ASM.

  9. Parents or caregivers must be able to keep accurate seizure diaries

  10. Subject is either not of childbearing potential, defined as premenarchal, postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy), if of childbearing potential, must comply with an acceptable method of birth control during the study, for at least 4 weeks prior to study entry and for 4 weeks following completion of the study, if able.

  11. Subject and/or caregiver(s)/legal representative must be willing and able to give informed assent/consent for participation in the study

  12. Subject and their caregiver must be willing and able (in the investigator's opinion) to comply with all study requirements

  13. History of COVID-19 vaccination is permitted

Exclusion Criteria:

  1. Etiology of subject's seizures is a progressive neurologic disease. Subjects with tuberous sclerosis will not be excluded from study participation, unless there is a progressive brain tumor
  2. Evidence of clinically significant disease (e.g., cardiac, respiratory, gastrointestinal, renal disease, hepatic disease) that in the opinion of the investigator(s) could affect the subject's safety or study conduct
  3. Subjects who were on adrenocorticotropic hormone (ACTH) therapy in the 6 months prior to baseline
  4. Subject on dietary therapy for less than 4 weeks prior to screening visit (Visit 1) or suffers from frequent stooling
  5. Current use of felbamate with less than 18 months of continuous exposure
  6. Concomitant use of vigabatrin: subjects who took vigabatrin in the past must be discontinued for at least 5 months before Visit 1 and must have documentation showing no evidence of a vigabatrin-associated clinically significant abnormality in an automated visual perimetry test, if able.
  7. Subject who had a history of hypoxia which needed emergency resuscitation within 12 months prior to baseline
  8. Status epilepticus within 12 weeks prior to Visit 1
  9. Any clinically significant illness (including COVID-19) in the 4 weeks prior to Visit 1, as evaluated by the Investigator
  10. Subject has clinically significant abnormal laboratory values, in the investigator's opinion, at Visit 1 or time of randomization (Visit 2)
  11. Subject has a history of any serious drug-induced hypersensitivity, e.g., toxic epidermal necrolysis, or Drug Reaction with Eosinophilia and Systemic Symptoms [DRESS]) or any drug-related rash requiring hospitalization
  12. Vagus Nerve Stimulation (VNS), Deep Brain Stimulation (DBS), Responsive Neurostimulator System (RNS) or other neurostimulation for epilepsy device implanted or activated <5 months year prior to enrollment. Stimulation parameters that have been stable for <4 weeks, or Battery life of unit not anticipated to extend for duration of trial.
  13. Subject is pregnant, may be pregnant, lactating or planning to be pregnant
  14. Any suicidal ideation with intent, with or without a plan within 6 months before Visit 2 (i.e., answering "Yes" to questions 4 or 5 in the Suicidal Ideation section of the age- specific Columbia-Suicide Severity Rating Scale (C-SSRS) in subjects aged 6 and above who are able to be evaluated
  15. Any suicidal behavior within 2 years before Visit 2 (i.e., answering YES to any question in the Suicidal behavior section of the age-specific Columbia-Suicide Severity Rating Scale (C-SSRS) in subjects aged 6 and above who are able to be evaluated.
  16. Evidence of significant active hepatic disease. Stable elevations of liver enzymes (alanine aminotransferase (ALT), and aspartate aminotransferase (AST)) due to concomitant medication(s) will be allowed if they are <3 x ULN
  17. Subject with total bilirubin [TBL] >2 x ULN (except for Gilbert's syndrome).
  18. Active viral hepatitis (B or C) as demonstrated by positive serology at the Screening visit (Visit 1)
  19. History of positive antibody/antigen test for human immunodeficiency virus (HIV)
  20. If taking Epidiolex, subject may not use other approved cannabidiol or over the counter cannabidiol products
  21. Scheduled for epilepsy-related surgery, VNS insertion, or any other stimulators/surgery during the projected course of the study
  22. Subject who has taken or used any investigational drug or device in the 4 weeks prior to the screening visit (Visit 1)
  23. Concomitant use of medications known to be strong inducers of cytochrome P450 (CYP3A) including, but not limited to: phenobarbital, phenytoin, carbamazepine, primidone, rifampin, troglitazone, St. John's Wort, efavirenz, nevirapine, glucocorticoids (other than topical usage), modafinil, pioglitazone, and rifabutin
  24. Evidence of cardiac disease, including unstable angina, myocardial infarction, within the past 2 years, uncontrolled heart failure, major arrhythmias, congenital short QT syndrome
  25. Subject with a short QTc interval (<340 msec) or long QTc interval (>460 msec) as confirmed by a repeated electrocardiogram (ECG)
  26. Benzodiazepine rescue administered on average more than once a week in the month before Visit 1
  27. Previous exposure to carisbamate or sensitivity/allergy to components of the oral suspension.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:Carisbamate 200 mg BID arm

Age: 4 to <12y* Titration: 2 mg/kg BID Maintenance: 4 mg/kg BID

Age: ≥12 y Titration: 100 mg BID Maintenance: 200 mg BID

Adolescent subjects 12 to 18 years old will receive the same dose as adults. Subjects 4 to < 12 years old in the carisbamate 200 mg BID arm will receive 4 mg/kg BID (not to exceed 200 mg BID [or a total of 400 mg per day]).

Subjects 4 to < 12 years old in the carisbamate 300 mg BID arm will receive 5.5 mg/kg BID (not to exceed 300 mg BID [or a total of 600 mg per day]).

实验性的:Carisbamate 300 mg BID arm

Age: 4 to <12y* Titration: 2.75 mg/kg BID Maintenance: 5.5 mg/kg BID

Age: ≥12 y Titration: 150 mg BID Maintenance: 300 mg BID

Adolescent subjects 12 to 18 years old will receive the same dose as adults. Subjects 4 to < 12 years old in the carisbamate 200 mg BID arm will receive 4 mg/kg BID (not to exceed 200 mg BID [or a total of 400 mg per day]).

Subjects 4 to < 12 years old in the carisbamate 300 mg BID arm will receive 5.5 mg/kg BID (not to exceed 300 mg BID [or a total of 600 mg per day]).

安慰剂比较:Placebo matched to 200 mg BID arm

Age: 4 to <12y* Titration: Volume equivalent to 2 mg/kg BID Maintenance: Volume equivalent to 4 mg/kg BID

Age: ≥12 y Titration: Volume equivalent to 100 mg BID Maintenance: Volume equivalent to 200 mg BID

Adolescent subjects 12 to 18 years old will receive the same dose as adults. Subjects 4 to < 12 years old in the carisbamate 200 mg BID arm will receive 4 mg/kg BID (not to exceed 200 mg BID [or a total of 400 mg per day]).

Subjects 4 to < 12 years old in the carisbamate 300 mg BID arm will receive 5.5 mg/kg BID (not to exceed 300 mg BID [or a total of 600 mg per day]).

安慰剂比较:Placebo matched to 300 mg BID arm

Age: 4 to <12y* Titration: Volume equivalent to 2.75 mg/kg BID Maintenance: Volume equivalent to 5.5 mg/kg BID

Age: ≥12 y Titration: Volume equivalent to 150 mg BID Maintenance: Volume equivalent to 300 mg BID

Adolescent subjects 12 to 18 years old will receive the same dose as adults. Subjects 4 to < 12 years old in the carisbamate 200 mg BID arm will receive 4 mg/kg BID (not to exceed 200 mg BID [or a total of 400 mg per day]).

Subjects 4 to < 12 years old in the carisbamate 300 mg BID arm will receive 5.5 mg/kg BID (not to exceed 300 mg BID [or a total of 600 mg per day]).

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Primary outcome will be the percentage change from baseline in the total frequency (average per 28 days) of countable drop seizures with potential to fall (tonic, atonic, tonic-clonic) seizures during the double-blind treatment period.
大体时间:3 years

Efficacy of Carisbamate YKP509

3 years

次要结果测量

结果测量
措施说明
大体时间
The percentage of subjects with at least a 50% reduction from baseline in the total frequency of drop seizures (tonic, atonic, tonic-clonic) during the double-blind treatment period.
大体时间:3 years

Efficacy of Carisbamate YKP509

3 years
Percentage change from baseline in the frequency of all types of seizures (total seizures) during the double-blind treatment period.
大体时间:3 years

Efficacy of Carisbamate YKP509

3 years
Subject/Caregiver Global Impression of Change (S/CGIC) in overall condition score at the last visit.
大体时间:3 years

Efficacy of Carisbamate YKP509- Scoring will be from 1 to 7 with 1 (very much improved) to 7 (very much worse)

3 years

其他结果措施

结果测量
措施说明
大体时间
Percentage change from baseline in the 28-day frequency of: drop seizures (tonic, atonic, tonic-clonic); non-drop seizures (myoclonic seizures, atypical absence); total seizures during the maintenance phase of the double-blind treatment period.
大体时间:3 years

Efficacy of Carisbamate YKP509

3 years
Percentage change from baseline in non-drop seizures (myoclonic seizures, atypical absence) frequency per 28 days during the during the double-blind treatment period.
大体时间:3 years

Efficacy of Carisbamate YKP509

3 years
The percentage of subjects with at least a 50% reduction from baseline in the total frequency of drop seizures (tonic, atonic, tonic-clonic) during the maintenance phase of the double-blind treatment period.
大体时间:3 years

Efficacy of Carisbamate YKP509

3 years
Proportion of subjects with a 75%, 90% and 100% response rate for drop seizures (tonic, atonic, tonic-clonic), non-drop seizures, and total seizures during the double-blind treatment period.
大体时间:3 years

Efficacy of Carisbamate YKP509

3 years
Proportion of subjects with a 75%, 90% and 100% response rate for drop seizures (tonic, atonic, tonic-clonic), non-drop seizures, and total seizures during the maintenance phase of the double-blind treatment period.
大体时间:3 years

Efficacy of Carisbamate YKP509

3 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Marc Kamin, MD、SK Life Science, Inc.

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2022年4月28日

初级完成 (估计的)

2027年2月1日

研究完成 (估计的)

2028年12月1日

研究注册日期

首次提交

2022年1月6日

首先提交符合 QC 标准的

2022年1月20日

首次发布 (实际的)

2022年2月2日

研究记录更新

最后更新发布 (实际的)

2026年11月6日

上次提交的符合 QC 标准的更新

2026年11月3日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅